Pfizer (NYSE:PFE) Trading Down 2.6% – Here’s Why

Pfizer Inc. (NYSE:PFE) shares traded down 2.6% during trading on Tuesday . The company traded as low as $26.78 and last traded at $27.0950. 46,067,441 shares traded hands during mid-day trading, an increase of 1% from the average session volume of 45,456,918 shares. The stock had previously closed at $27.83.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Bank of America dropped their price target on Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a research note on Monday, December 15th. Royal Bank Of Canada started coverage on Pfizer in a research note on Tuesday, February 24th. They issued an “underperform” rating and a $25.00 price target for the company. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research report on Thursday, January 22nd. Morgan Stanley set a $27.00 target price on Pfizer and gave the stock a “positive” rating in a research report on Tuesday, March 17th. Finally, Guggenheim raised their target price on Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, March 24th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have issued a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $28.19.

Pfizer Stock Performance

The firm has a market capitalization of $154.07 billion, a P/E ratio of 19.92 and a beta of 0.43. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71. The company has a 50-day moving average of $27.13 and a 200-day moving average of $25.87.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.57 by $0.09. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The business had revenue of $17.56 billion during the quarter, compared to analyst estimates of $16.93 billion. During the same period last year, the company earned $0.63 EPS. Pfizer’s revenue for the quarter was down 1.2% compared to the same quarter last year. On average, equities analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Institutional Trading of Pfizer

A number of large investors have recently bought and sold shares of the business. Stance Capital LLC grew its holdings in Pfizer by 26,746.0% during the 4th quarter. Stance Capital LLC now owns 26,846 shares of the biopharmaceutical company’s stock worth $668,000 after acquiring an additional 26,746 shares during the period. Rockefeller Capital Management L.P. grew its holdings in Pfizer by 27.1% during the 4th quarter. Rockefeller Capital Management L.P. now owns 1,842,275 shares of the biopharmaceutical company’s stock worth $45,873,000 after acquiring an additional 392,913 shares during the period. World Investment Advisors grew its holdings in Pfizer by 11.2% during the 4th quarter. World Investment Advisors now owns 397,952 shares of the biopharmaceutical company’s stock worth $9,909,000 after acquiring an additional 40,239 shares during the period. Nalls Sherbakoff Group LLC acquired a new stake in Pfizer during the 4th quarter worth about $92,000. Finally, DUTCH ASSET Corp acquired a new stake in Pfizer during the 4th quarter worth about $237,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.